Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy

Journal of the American College of Cardiology

Volumn 56, Issue 25, 2010, Pages 2115-2125

  Rajesh, Mohanraj ^a   Mukhopadhyay, Partha ^a   Btkai, Sndor ^a   Patel, Vivek ^a   Saito, Keita ^b   Matsumoto, Shingo ^b   Kashiwaya, Yoshihiro ^a   Horvth, Bla ^a   Mukhopadhyay, Bani ^a   Becker, Lauren ^a   Hask, Gyrgy ^c   Liaudet, Lucas ^d   Wink, David A ^b   Veves, Aristidis ^e   Mechoulam, Raphael ^f   Pacher, Pl ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

cannabinoids; diabetic complications; inflammation; oxidative stress

Indexed keywords

CANNABIDIOL; CASPASE 3; CASPASE 7; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DEATH; CHROMATIN; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DRUG SAFETY; DRUG TOLERABILITY; ELECTRON SPIN RESONANCE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PERFORMANCE; HEART VENTRICLE FUNCTION; HEART VENTRICLE PRESSURE; HEART VOLUME; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MOUSE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPASTICITY;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CANNABIDIOL; CELLS, CULTURED; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FIBROSIS; GLUCOSE; HEMODYNAMICS; HUMANS; INSULIN; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; NF-KAPPA B; OXIDATIVE STRESS; PANCREAS; REACTIVE OXYGEN SPECIES;

EID: 78649984380     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.07.033     Document Type: Article

References (33)

1. F.S. Fein Diabetic cardiomyopathy Diabetes Care 13 1990 1169 1179
2. T.J. Regan, S. Ahmed, B. Haider, C. Moschos, and A. Weisse Diabetic cardiomyopathy: experimental and clinical observations N J Med 91 1994 776 778
3. J. Asbun, and F.J. Villarreal The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy J Am Coll Cardiol 47 2006 693 700
4. J. Kajstura, F. Fiordaliso, and A.M. Andreoli IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress Diabetes 50 2001 1414 1424
5. P. Pacher, J.S. Beckman, and L. Liaudet Nitric oxide and peroxynitrite in health and disease Physiol Rev 87 2007 315 424
6. L. Cai, Y. Wang, and G. Zhou Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy J Am Coll Cardiol 48 2006 1688 1697
7. Y. Wang, W. Feng, and W. Xue Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling Diabetes 58 2009 1391 1402
8. M. Aragno, R. Mastrocola, and C. Medana Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes Endocrinology 147 2006 5967 5974
9. N. Mariappan, C.M. Elks, and S. Sriramula NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes Cardiovasc Res 85 2010 473 483
10. P. Pacher, L. Liaudet, F.G. Soriano, J.G. Mabley, E. Szabo, and C. Szabo The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes Diabetes 51 2002 514 521 (Pubitemid 34764811)
11. D. Westermann, S. Rutschow, and S. Van Linthout Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus Diabetologia 49 2006 2507 2513
12. R.A. Thandavarayan, K. Watanabe, and M. Ma Dominant-negative p38{alpha} mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus Am J Physiol Heart Circ Physiol 297 2009 H911 H919
13. S. Van Linthout, F. Spillmann, and A. Riad Human apolipoprotein a-I gene transfer reduces the development of experimental diabetic cardiomyopathy Circulation 117 2008 1563 1573
14. A. Frustaci, J. Kajstura, and C. Chimenti Myocardial cell death in human diabetes Circ Res 87 2000 1123 1132
15. D. Westermann, S. Rutschow, and S. Jager Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism Diabetes 56 2007 641 646
16. P. Pacher, S. Batkai, and G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol Rev 58 2006 389 462
17. P. Pacher, and S. Steffens The emerging role of the endocannabinoid system in cardiovascular disease Semin Immunopathol 31 2009 63 77
18. M.P. Barnes Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain Expert Opin Pharmacother 7 2006 607 615
19. B.F. Thomas, A.F. Gilliam, D.F. Burch, M.J. Roche, and H.H. Seltzman Comparative receptor binding analyses of cannabinoid agonists and antagonists J Pharmacol Exp Ther 285 1998 285 292
20. A.A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, and R. Mechoulam Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Trends Pharmacol Sci 30 2009 515 527
21. J.M. Cunha, E.A. Carlini, and A.E. Pereira Chronic administration of cannabidiol to healthy volunteers and epileptic patients Pharmacology 21 1980 175 185
22. P. Consroe, J. Laguna, and J. Allender Controlled clinical trial of cannabidiol in Huntington's disease Pharmacol Biochem Behav 40 1991 701 708
23. R. Durst, H. Danenberg, and R. Gallily Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury Am J Physiol Heart Circ Physiol 293 2007 H3602 H3607
24. Y. Gaoni, and R. Mechoulam The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish J Am Chem Soc 93 1971 217 224
25. P. Mukhopadhyay, S. Btkai, and M. Rajesh Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity J Am Coll Cardiol 50 2007 528 536
26. P. Pacher, T. Nagayama, P. Mukhopadhyay, S. Batkai, and D.A. Kass Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats Nat Protocols 3 2008 1422 1434
27. P. Mukhopadhyay, M. Rajesh, G. Hasko, B.J. Hawkins, M. Madesh, and P. Pacher Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy Nat Protocols 2 2007 2295 2301
28. L. Weiss, M. Zeira, and S. Reich Cannabidiol arrests onset of autoimmune diabetes in NOD mice Neuropharmacology 54 2008 244 249
29. A.B. El-Remessy, M. Al-Shabrawey, Y. Khalifa, N.T. Tsai, R.B. Caldwell, and G.I. Liou Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes Am J Pathol 168 2006 235 244
30. D. Westermann, S. Van Linthout, and S. Dhayat Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy Basic Res Cardiol 102 2007 500 507
31. A.J. Hampson, M. Grimaldi, J. Axelrod, and D. Wink Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants Proc Natl Acad Sci USA 95 1998 8268 8273
32. A.M. Malfait, R. Gallily, and P.F. Sumariwalla The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis Proc Natl Acad Sci USA 97 2000 9561 9566
33. E. Kozela, M. Pietr, A. Juknat, N. Rimmerman, R. Levy, and Z. Vogel Cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells J Biol Chem 285 2010 1616 1626